Tirzepatide: A Research Overview

Introduction

Tirzepatide (development code LY3298176) is a synthetic peptide compound classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Eli Lilly and Company, it was the first molecule in its pharmacological class to reach regulatory approval — a distinction that has made it a sustained subject of scientific attention in cardiometabolic research. This article provides an educational reference overview of tirzepatide's chemical identity, pharmacological classification, and regulatory history based on published primary literature and official regulatory documents.

Background

The incretin system — comprising intestinally derived peptide hormones that modulate insulin secretion in a glucose-dependent manner — has been a focus of cardiometabolic research for several decades. Two principal incretin hormones, GIP and GLP-1, were characterized through independent lines of research beginning in the 1970s and 1980s. Therapeutic exploitation of these pathways first produced selective GLP-1 receptor agonists for type 2 diabetes management. Tirzepatide represented a subsequent and pharmacologically distinct development: a single synthetic molecule engineered to engage both incretin receptor subtypes simultaneously, creating a class with no prior approved precedent.

The foundational preclinical and early clinical characterization of tirzepatide was reported by Coskun and colleagues in 2018, describing the molecule under its experimental designation LY3298176 [1]. That paper documented the compound's design rationale, receptor binding profile, and early human pharmacokinetic data, establishing tirzepatide's scientific identity in the peer-reviewed record.

Chemistry and Structure

Tirzepatide is a 39-amino acid synthetic peptide. Its primary sequence was derived from the native human GIP sequence, which provides the structural scaffold for high-affinity GIP receptor engagement. Modifications to the sequence and the addition of a C20 fatty diacid moiety — attached via a linker to a lysine residue — were incorporated to extend the molecule's plasma half-life and enable extended-interval dosing in clinical settings [1].

The fatty acid modification facilitates reversible albumin binding in circulation, a strategy that substantially prolongs the molecule's residence time relative to native incretin peptides. Native GIP and GLP-1 have biological half-lives measured in minutes due to rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4); tirzepatide's albumin-binding design was engineered to overcome this limitation.

The molecular weight of tirzepatide is approximately 4,813 daltons. In clinical formulations it is administered as a sterile aqueous solution.

Pharmacological Classification

Tirzepatide is classified as a dual GIP receptor and GLP-1 receptor agonist — referred to in the scientific literature as a "twincretin" or dual incretin receptor agonist. This pharmacological designation places it in a distinct class from selective GLP-1 receptor agonists (such as semaglutide or liraglutide), which engage only the GLP-1 receptor subtype.

Willard and colleagues (2020) characterized the molecular pharmacology of tirzepatide in detail, reporting that the molecule displays an imbalanced receptor engagement profile: it behaves as a full agonist at the GIP receptor while acting as a biased agonist at the GLP-1 receptor, favoring cyclic AMP (cAMP) generation over beta-arrestin recruitment [2]. The structural basis for this dual receptor agonism was further elaborated in a 2022 cryo-electron microscopy study published in the Proceedings of the National Academy of Sciences, which identified the molecular determinants of receptor engagement at both receptor complexes [3]. Together these studies established tirzepatide as a pharmacologically novel probe for studying the respective contributions of two incretin pathways. A detailed account of these findings is covered in the tirzepatide mechanism of action article.

Regulatory Status

Tirzepatide received its first regulatory approval from the United States Food and Drug Administration (FDA) on May 13, 2022, under the brand name Mounjaro, for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (NDA 215866) [4]. This made tirzepatide the first FDA-approved dual GIP and GLP-1 receptor agonist — a milestone for the incretin pharmacology field.

On November 8, 2023, the FDA granted a second approval to tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbidity [5]. A further indication for obstructive sleep apnea was approved in December 2024, marking a third distinct therapeutic context recognized by the agency.

Tirzepatide's regulatory status as an approved prescription pharmaceutical in the United States and its use as a research-use-only material in non-clinical research contexts are distinct and governed by separate frameworks. Researchers seeking verified material can find batch-specific analytical data on the tirzepatide product page.

Discovery History

The scientific lineage of tirzepatide traces through decades of incretin biology. GIP was first isolated and characterized in the early 1970s by Brown and colleagues at the University of British Columbia. GLP-1 was identified as a biologically active incretin in the 1980s through the work of researchers including Joel Habener, Svetlana Mojsov, Daniel Drucker, and Jens Juul Holst, following molecular cloning of the proglucagon gene.

The scientific hypothesis that simultaneous activation of both GIP and GLP-1 receptors might produce metabolic effects beyond those achievable by selective GLP-1 receptor agonism alone drove a research program at Eli Lilly and Company. That program culminated in the identification of LY3298176 (tirzepatide). The compound's design, preclinical characterization, and initial phase 1 human data were first reported in the peer-reviewed literature in 2018 [1], marking the public debut of the molecule that would advance through one of the most extensive clinical development programs in the incretin pharmacology field.

References

1. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. DOI: 10.1016/j.molmet.2018.09.009

2. Willard FS, Douros JD, Gabe MBN, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32730231. DOI: 10.1172/jci.insight.140532

3. Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA. 2022;119(13):e2116506119. PMID: 35333651. DOI: 10.1073/pnas.2116506119

4. US Food and Drug Administration. Mounjaro (tirzepatide) injection: NDA 215866 approval letter. May 13, 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215866Orig1s000ltr.pdf

5. US Food and Drug Administration. FDA approves new medication for chronic weight management. Press announcement. November 8, 2023. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management